New Delhi: Concerns are growing over a newly emerging COVID-19 variant, PJ.2.1, which is spreading across several parts of the world. The variant, belonging to SARS-CoV-2, was first identified in Ontario, Canada, on May 2, 2026, and has since been detected across North America, Europe, Asia and Oceania.

Researchers have described PJ.2.1 as a “saltation variant”, meaning it emerged with multiple genetic changes at once rather than accumulating mutations gradually over time. Scientists have observed several mutations in its spike protein, which plays a crucial role in allowing the virus to enter human cells.

PJ.2.1 Variant Spreading Across Multiple Continents

The new variant has reportedly demonstrated rapid growth in several regions, attracting the attention of researchers and public health experts.

However, current evidence does not indicate that PJ.2.1 causes more severe illness than previously circulating COVID-19 variants. Preliminary laboratory findings also do not suggest significantly greater escape from vaccine-induced immunity compared with several other variants.

The World Health Organization has not formally designated PJ.2.1 as a Variant of Interest or Variant of Concern. Its emergence and spread are nevertheless being examined through ongoing scientific research and genomic surveillance.

Has PJ.2.1 Been Detected in India?

As of the information cited in the available reports, there has been no confirmed report of PJ.2.1 detection in India.

Scientists continue to monitor the evolution of SARS-CoV-2 through genomic surveillance to identify emerging variants and understand their potential public health implications.

What Are the Symptoms of the PJ.2.1 COVID Variant?

The symptoms associated with PJ.2.1 appear similar to those commonly reported with other COVID-19 infections and respiratory illnesses.

Common symptoms include:

- Fever

- Cough

- Runny or blocked nose

- Sore throat

- Fatigue and weakness

- Headache and body aches

Some individuals may experience more pronounced throat discomfort or prolonged fatigue. In certain cases, breathing difficulties, gastrointestinal symptoms, or changes in smell and taste may also occur.

Should People Be Worried About PJ.2.1?

Although the rapid spread of PJ.2.1 has attracted attention, experts caution against unnecessary panic. Available evidence does not currently establish that the variant causes more severe disease or substantially reduces protection against severe illness provided by vaccination.

Public health monitoring, vaccination among eligible high-risk groups, appropriate testing and timely medical consultation remain important measures.

People experiencing breathing difficulties or other severe symptoms should seek medical attention promptly.

Continued Monitoring Remains Important

The emergence of PJ.2.1 highlights the continued evolution of COVID-19 several years after the pandemic.

While its spread across multiple continents warrants scientific attention, further research and surveillance will be necessary to determine its long-term epidemiological significance and potential impact on public health.

For now, experts emphasise the importance of staying informed through reliable health authorities while avoiding unnecessary alarm.